PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: stock market

The PATH study - CIDP Treatment With …

1 Hizentra CIDP (PATH) IgPro20_3003 K. Goodwin 21 Nov. 2012 The PATH study - CIDP Treatment with subcutaneous immunoglobulin ( igpro20 ) CSL Behring is currently recruiting patients for the PATH study , an international clinical trial designed to evaluate the effectiveness of igpro20 compared with placebo in the Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The study will also look at the safety and tolerability of these doses. Intravenous immunoglobulins (IVIG), steroids and plasma exchange are recommended Treatment options for CIDP, although only one IVIG has received official marketing approval.

1 Hizentra CIDP (PATH) – IgPro20_3003 K. Goodwin 21 Nov. 2012 The PATH study - CIDP Treatment With Subcutaneous Immunoglobulin (IgPro20) CSL Behring is currently recruiting patients for the PATH study, an international clinical

Loading..

Tags:

  With, Treatment, Subcutaneous, Immunoglobulin, Ipdc, Cidp treatment with subcutaneous immunoglobulin, Igpro20

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of The PATH study - CIDP Treatment With …

Related search queries